Tradestie Institutional Equity Comparison Engine

STTK vs CVM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

STTK Overall Edge

STTK Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Shattuck Labs, Inc. Common Stock (STTK) driven by superior Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, STTK trades at N/M Forward P/E with 0.0% operating margin (-66.6% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, STTK sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
STTK N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY -66.6% vs -62.7%
Momentum & Technical Winner STTK
1Y +147.8% vs -77.5% ยท 52W Pos 43% vs 10%
Options & Structure Winner STTK
BREAKDOWN (10th %ile IV) vs BREAKDOWN (N/A IV)
STTK NASDAQ
Shattuck Labs, Inc. Common Stock
Pharmaceutical Preparations
$4.56
-1.94% 1D
Market Cap $474.6M
1M Return -15.87%
1Y Return +147.83%
Forward P/E N/M
Unified AI Score
51.1 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 63.0 Mom 60.0
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: STTK +147.83% CVM -77.48% Spread: +218.53 pp (STTK Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period STTK Revenue CVM Revenue STTK Op. Margin CVM Op. Margin Margin Edge
FY2014 N/A $0M N/A -9721.4% CVM
FY2019 $10M N/A -253.5% N/A STTK
FY2020 $10M N/A -371.8% N/A STTK
FY2021 $30M N/A -150.8% N/A STTK
FY2022 $0M N/A -15848.0% N/A STTK
FY2023 $0M N/A -5549.6% N/A STTK
FY2024 $10M N/A -1408.3% N/A STTK
FY2025 $0M N/A -5150.8% N/A STTK

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: STTK (4) vs CVM (4)
Institutional Metric STTK CVM Criterion Row Winner
Market Capitalization Scale $474.6M $20.9M Larger Scale STTK
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY) Growth -66.6% -62.7% Higher Growth CVM
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -47.2% -252.5% Higher ROE STTK
52-Week Range Position Momentum 43% ($2โ€“$8) 10% ($1โ€“$8) Stronger Trend STTK
Beta / 30D Volatility Risk Regime 1.48ฮฒ ยท 78% Vol 0.65ฮฒ ยท 120% Vol Lower Realized Risk STTK
Unified Institutional Score Composite Signal 51.1 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full STTK vs CVM Buy Guide
STTK BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live STTK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither STTK nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.